Now, a research team led by Prof. Dr. Kai Wollert, Head of Molecular and Translational Cardiology at the Department of Cardiology and Angiology at Hannover Medical School (MHH), has discovered that a microprotein called BRICK1 plays a key role in this process.
A new study published in Cell from a team of investigators from the Stanford Departments of Urology and Radiation Oncology, in close collaboration with colleagues from Stanford Cancer Institute, offers a powerful new approach: using a non-invasive urine test to determine, at a molecular level, who benefits from additional therapy—and who does not.
MILFORD, Mass., April 8, 2026 /PRNewswire/ — Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening.